Cyclopropylamines as LSD1 inhibitors
This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
1. A method of treating a hematologic cancer which comprises administering to a human in need thereof an effective amount of a compound which is 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid, represented by the formula:
or a pharmaceutically acceptable salt thereof, wherein said hematologic cancer is selected from the group consisting of: acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, and non-Hodgkin's lymphoma.
2. The method of claim 1 wherein said hematologic cancer is myelodysplastic syndrome.
3. The method of claim 1 , further comprising administering an additional therapeutic agent selected from the group consisting of tretinoin, azacitidine, and decitabine.
4. The method of claim 3 , wherein said additional therapeutic agent is tretinoin.
5. The method of claim 3 , wherein said additional therapeutic agent is azacitidine.
6. The method of claim 3 , wherein said additional therapeutic agent is decitabine.
7. The method of claim 3 , wherein said hematologic cancer is myelodysplastic syndrome.
8. The method of claim 4 , wherein said hematologic cancer is myelodysplastic syndrome.
9. The method of claim 5 , wherein said hematologic cancer is myelodysplastic syndrome.
10. The method of claim 6 , wherein said hematologic cancer is myelodysplastic syndrome.
11. The method of claim 3 , wherein said hematologic cancer is acute myeloid leukemia.
12. The method of claim 4 , wherein said hematologic cancer is acute myeloid leukemia.
13. The method of claim 5 , wherein said hematologic cancer is acute myeloid leukemia.
14. The method of claim 6 , wherein said hematologic cancer is acute myeloid leukemia.